17 September 2025 marks the start of the inaugural BioCentury Inc. Grand Rounds – Europe, hosted in Cambridge and focused on “Bridging Academia and Industry for Breakthrough Innovation”.

We’re proud to support this landmark event and for the expanding Campus to be part of the growing Cambridge ecosystem. The Grand Rounds will bring together investors and leaders from biotech, pharma, R&D and academia to showcase groundbreaking research, uncover clinical insights and highlight the innovative technologies with significant commercial potential.

Over the next few days, the programme will:
·        Unlock transformative breakthroughs by exploring disease biology, therapeutic modalities and enabling technologies
·        Stimulate debate with key thought leaders about obstacles and opportunities in translation
·        Showcase cutting-edge science with commercial potential and provide industry insights

We’re delighted that Robert Evans is representing Wellcome Genome Campus on the regional host committee alongside champions of the region including Kathryn Chapman, Executive Director, Innovate Cambridge and Anne Horgan (nee Nguyen), Ph.D., Partner at Cambridge Innovation Capital (CIC).

Major speakers across the three days include: Kate Bingham, Managing Partner, SV Health Investors; Shaun Grady, Chair, U.K., AstraZeneca; Steve Jackson, Ph.D., Professor of Biology, Cambridge & Group Leader, CRUK-CI; James Sabry, M.D., Ph.D., EVP & Chief Business Officer, BioMarin; Patrick Vallance, KCB, Minister of State for Science, Research & Innovation; and Sarah Teichmann FMedSci FRS, Ph.D., Professor & Chair, Cambridge Stem Cell Institute & GSK

Wellcome Genome Campus will be showcasing future plans and opportunities at the host committee stand.